KR20230047056A - 유방암 치료제 - Google Patents

유방암 치료제 Download PDF

Info

Publication number
KR20230047056A
KR20230047056A KR1020227045161A KR20227045161A KR20230047056A KR 20230047056 A KR20230047056 A KR 20230047056A KR 1020227045161 A KR1020227045161 A KR 1020227045161A KR 20227045161 A KR20227045161 A KR 20227045161A KR 20230047056 A KR20230047056 A KR 20230047056A
Authority
KR
South Korea
Prior art keywords
breast cancer
estrogen receptor
acceptable salt
pharmacologically acceptable
therapeutic agent
Prior art date
Application number
KR1020227045161A
Other languages
English (en)
Korean (ko)
Inventor
사토시 가와노
사오리 미야노
교코 니시바타
사요 후쿠시마
Original Assignee
에자이 알앤드디 매니지먼트 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에자이 알앤드디 매니지먼트 가부시키가이샤 filed Critical 에자이 알앤드디 매니지먼트 가부시키가이샤
Publication of KR20230047056A publication Critical patent/KR20230047056A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
KR1020227045161A 2020-07-31 2021-07-29 유방암 치료제 KR20230047056A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JPJP-P-2020-130935 2020-07-31
JP2020130935 2020-07-31
JPJP-P-2020-163258 2020-09-29
JP2020163258 2020-09-29
PCT/JP2021/028008 WO2022025150A1 (ja) 2020-07-31 2021-07-29 乳がん治療剤

Publications (1)

Publication Number Publication Date
KR20230047056A true KR20230047056A (ko) 2023-04-06

Family

ID=80035757

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227045161A KR20230047056A (ko) 2020-07-31 2021-07-29 유방암 치료제

Country Status (11)

Country Link
US (1) US20230172924A1 (pt)
EP (1) EP4151212A4 (pt)
JP (1) JPWO2022025150A1 (pt)
KR (1) KR20230047056A (pt)
CN (1) CN115996722A (pt)
AU (1) AU2021315234A1 (pt)
BR (1) BR112022027069A2 (pt)
CA (1) CA3185174A1 (pt)
MX (1) MX2023000060A (pt)
TW (1) TW202220652A (pt)
WO (1) WO2022025150A1 (pt)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014235614A (ja) 2013-06-03 2014-12-15 株式会社ゼネット 総合学習支援ネットワークシステム及び総合学習支援方法
JP2017217935A (ja) 2016-06-03 2017-12-14 株式会社東海理化電機製作所 ステアリングスイッチ装置
KR20180015079A (ko) 2016-08-02 2018-02-12 다이요 유덴 가부시키가이샤 적층 세라믹 콘덴서
US20180303817A1 (en) 2015-12-17 2018-10-25 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
WO2019189241A1 (ja) 2018-03-28 2019-10-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝細胞癌治療剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013116293A1 (en) * 2012-01-31 2013-08-08 Novartis Ag Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
ES2914072T3 (es) 2014-08-18 2022-06-07 Eisai R&D Man Co Ltd Sal de derivado de piridina monocíclico y su cristal
CN114984013A (zh) 2015-03-25 2022-09-02 国立癌症研究中心 胆管癌治疗剂
US20230149381A1 (en) * 2020-04-17 2023-05-18 Eisai R&D Management Co., Ltd. Breast cancer therapeutic agent

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014235614A (ja) 2013-06-03 2014-12-15 株式会社ゼネット 総合学習支援ネットワークシステム及び総合学習支援方法
US20180303817A1 (en) 2015-12-17 2018-10-25 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
JP2017217935A (ja) 2016-06-03 2017-12-14 株式会社東海理化電機製作所 ステアリングスイッチ装置
KR20180015079A (ko) 2016-08-02 2018-02-12 다이요 유덴 가부시키가이샤 적층 세라믹 콘덴서
WO2019189241A1 (ja) 2018-03-28 2019-10-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝細胞癌治療剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
[비특허문헌 1] Howell et al.,"Comparison of Fulvestrant Versus Tamoxifen for the Treatment of Advanced Breast Cancer in Postmenopausal Women Previously Untreated With Endocrine Therapy: A Multinational, Double-Blind, Randomized Trial", Journal of Clinical Oncology, 2004, 22(9), 1605-1613.
[비특허문헌 2] Deeks et al.,"Exemestane A Review of its Use in Postmenopausal Women with Breast Cancer" Drugs, 2009, 69(7), 889-918

Also Published As

Publication number Publication date
AU2021315234A1 (en) 2023-01-19
BR112022027069A2 (pt) 2023-02-07
CN115996722A (zh) 2023-04-21
TW202220652A (zh) 2022-06-01
CA3185174A1 (en) 2022-02-03
WO2022025150A1 (ja) 2022-02-03
US20230172924A1 (en) 2023-06-08
EP4151212A4 (en) 2024-04-10
JPWO2022025150A1 (pt) 2022-02-03
MX2023000060A (es) 2023-02-01
EP4151212A1 (en) 2023-03-22

Similar Documents

Publication Publication Date Title
KR102318306B1 (ko) 암의 치료를 위한 조합 요법
CN101222850B (zh) 治疗对药物有抗性的癌症的方法
JP2016510748A (ja) 癌の処置のための組成物
CN101641013A (zh) 核受体结合剂
SK288546B6 (sk) 40-O-(2-hydroxyetyl)rapamycín v kombinácii s exemestánom alebo letrozolom na použitie pri liečení nádoru prsníka
JP2015536986A (ja) 併用療法
EP1845990B1 (en) Treatment of metastasized tumors
TW200843766A (en) Treatment of melanoma
EP3581183A1 (en) Tumor-treating pharmaceutical composition
CA3233554A1 (en) Combination therapy using a ptpn11 inhibitor and a kras g12c inhibitor
EP4003332A1 (en) Pharmaceutical composition of mdm2 inhibitor and use thereof for preventing and/or treating disease
KR20230047056A (ko) 유방암 치료제
US20230149381A1 (en) Breast cancer therapeutic agent
Thankan et al. Salinization Dramatically Enhance the Anti-Prostate Cancer Efficacies of AR/AR-V7 and Mnk1/2 Molecular Glue Degraders, Galeterone and VNPP433-3β Which Outperform Docetaxel and Enzalutamide in CRPC CWR22Rv1 Xenograft Mouse Model
JP6748704B2 (ja) 抗癌治療剤
WO2016012982A1 (en) Combination therapy for the treatment of resistant breast cancer
US20230000876A1 (en) Treating cancers with a cyclin-dependent kinase inhibitor
TW202342043A (zh) 使用ptpn11抑制劑及egfr抑制劑之組合療法
JP2023046235A (ja) 医薬組成物及びｓｔａｔ３のリン酸化阻害剤
WO2024130344A1 (en) Transient receptor potential vanilloid 6 inhibitors
WO2009138779A1 (en) Combination comprising 4- (3-chloro-2-fluoroanilino) -7-meth0xy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxyjquinazoline
TW201420102A (zh) 組合療法
US20090062246A1 (en) Therapeutic treatment-014